

PUBLICATIONS IN PEER-REVIEWED JOURNALS:

1. Van Jaarsveld PP, **Kotzé B**, Van der Walt BJ. Possibility that thyroglobulin consists of 2 non-identical half size subunits. *SA Journal of Science* 72:313-314, 1976.
2. Van der Walt B, **Kotzé B**, Edelhoch H, Van Jaarsveld P. Evidence that thyroglobulin contains nonidentical half molecule subunits. *J Biol Chem* 253:1853-1858, 1978.
3. Van der Walt B, **Kotzé B**, Van Jaarsveld P, Edelhoch H. Characterization of the major polypeptide chains of reduced bovine thyroglobulin. *Biochim Biophys Acta* 744:90-98, 1983.
4. Mouton R, **Huisamen B**, Lochner A. Increased myocardial inositol trisphosphate levels during β 1-adrenergic stimulation and reperfusion of ischaemic rat heart. *J Mol Cell Cardiol* 23:841-850, 1991.
5. Mouton R, **Huisamen B**, Lochner A. The effect of ischaemia and reperfusion on sarcolemmal inositol phospholipid and cytosolic inositol phosphate metabolism in the isolated perfused rat heart. *Mol Cell Biochem* 105:127-135, 1991.
6. Venter H, Genade S, Mouton R, **Huisamen B**, Harper IS, Lochner A. Myocardial membrane cholesterol: effects of ischaemia. *J Mol Cell Cardiol* 23:1271-1286, 1991.
7. Mouton R, Genade S, **Huisamen B**, Lochner A. Effects of ischaemia-reperfusion on [3H]-inositol phosphates and Ins(1,4,5)P₃ levels in cardiac atria and ventricles - a comparative study. *Mol Cell Biochem* 115:195-202, 1992.
8. Wiid IJF, **Huisamen B**. An inexpensive approach to ultracentrifugation of small volume samples. *Bio Techniques* 14:564, 1993.
9. **Huisamen B**, Mouton R, Lochner A. Demonstration of a specific saturable [3H]Ins(1,4,5)P₃ binding site in rat heart muscle. *J Mol Cell Cardiol* 26:341-349, 1994.
10. **Huisamen B**, Mouton R, Opie LH, Lochner A. Effects of ischaemia, reperfusion and β 1-adrenergic receptor stimulation on the inositoltrisphosphate receptor population in rat heart atria and ventricles. *Mol Cell Biochem* 140:23-30, 1994.
11. **Huisamen B**, Ellis E, Van Dyk M, Lochner. Characterization of inositolpolyphosphate binding to myocardial membranes. *Mol Cell Biochem* 162:1-9, 1996.
12. **Huisamen B**, Lochner A. Inositol polyphosphates and their binding proteins -a short review. *Mol Cell Biochem* 157:229-232, 1996.
13. **Huisamen B**. in Myocardial Metabolism - Part I & II. A Round-table discussion. *Cardiovascular J SA (A supplement of the SAMJ) Suppl 1:C45-C53*, 1997.
14. **Huisamen B**. Tumor necrosis factor- α - Mediator in type 2 diabetes? *Specialist Medicine*, July 1999.
15. Donthi RV, **Huisamen B**, Lochner A. Effect of vanadate and insulin on glucose transport in isolated adult rat cardiomyocytes. *Cardiovascular Drugs and Therapy* 14(5):463-470, 2000.
16. **Huisamen B**, Donthi RV, Lochner A. Insulin in combination with vanadate stimulates glucose transport in isolated cardiomyocytes from obese Zucker rats. *Cardvasc drugs Ther* 15:445-452, 2001.
17. **Huisamen B**, Marais E, Genade S, Lochner A. Serial changes in the myocardial β -adrenergic signalling system in two models of non-insulin dependent diabetes mellitus. *J Mol Cell Biochem* 219:73-82, 2001.
18. **Huisamen B**, Van Dyk M, Keyser A, Lochner A. The effects of insulin and β -adrenergic stimulation on glucose transport, GLUT 4 and PKB activation in the myocardium of lean and obese non-insulin dependent diabetes mellitus rats. *J Mol Cell Biochem* 223:15-25, 2001.
19. Salie R, Harper I, Cillie C, Genade S, **Huisamen B**, Moolman JA, Lochner A. Melatonin protects against ischaemic-reperfusion myocardial damage. *J Mol Cell Cardiol* 33: 343-357, 2001

20. Marais E, Genade S, Moolman JA, **Huisamen B**, Lochner A. Activation of p38 MAPK induced by a multi-cycle ischaemic preconditioning protocol is associated with attenuated p38 MAPK activity during sustained ischaemia and reperfusion. *J Mol Cell Cardiol* 33: 769-778, 2001.
21. Upton J, **Huisamen B**, Lochner A. cGMP levels of isolated rat papillary muscle during anoxia-reoxygenation *Cardvasc J S Afr* - 13(1):10-16, 2002.
22. **Huisamen B**. Protein Kinase B in the diabetic heart – an invited publication. *J Mol Cell Biochem*, 249:31-38, 2003.
23. Lochner A, Genade S, Hattingh S, Marais E, **Huisamen B**, Moolman JA. Comparison between ischaemic and anisomycin-induced preconditioning: role of p38 MAPK. *Cardiovasc Drugs Ther* 17:217-230, 2003.
24. **Huisamen B**, Upton JJ, Lochner A. A role for the β_1 -adrenergic signalling pathway in the response of papillary muscles from Type 2 diabetic hearts to anoxia-reoxygenation. *Cardiovasc Drugs and Ther* – 18:247-255, 2004.
25. Lochner A, Du Toit EF, **Huisamen B**, Koeslag JH, Moolman JA, Van Rooyen J. Cellular injury in ischaemia. *Cardiovasc J S Afr* 15:205-206, 2004.
26. Marais E, Genade S, Salie R, **Huisamen B**, Maritz S, Moolman JA, Lochner A. The temporal relationship between p38 MAPK and HSP27 activation in ischaemic and pharmacological preconditioning. *Basic Res Cardiol*. 100(1):35-47, 2005. Epub 2004 Nov 03.
27. **Huisamen B**, Lochner A. Exercise modulates myocardial protein kinase B/Akt in Zucker obese rats. *Heart* – 91:227-228, 2005.
28. Lecour S, Engerer A, **Huisamen B**, Opie LH. Pharmacological preconditioning with TNF involves STAT-3 activation rather than classic prosurvival kinases (Akt and Erk) at reperfusion. *Circulation* 112:3911-3918, 2005
29. **Huisamen B**, Genade S, Webster I, Lochner A. Signalling pathways activated by glucagon-like peptide-1 (7-36) amide in the heart and their role in protection against ischemia. *Cardiovasc J of Afr* 19(2):77-83, 2008.
30. Genade S, Genis A, Ytrehus K, **Huisamen B**, Lochner A. Melatonin receptor-mediated protection against myocardial ischaemia/reperfusion injury: role of its anti-adrenergic actions. *J Pineal Res* 45(4): 449-458, 2008.
31. Lochner A, Marais E, Genade S, **Huisamen B**, Du Toit EF, Moolman JA. Protection of the ischaemic heart: investigations into the phenomenon of ischaemic preconditioning. *Cardiovasc J Afr* 20(1): 43-51, 2009.
32. Fan WJ, Genade S, Genis A, **Huisamen B**, Lochner A. Dexamethasone-induced cardioprotection: A role for the phosphatase MKP-1? *Life Sci* 8 (Epub ahead of print) 2009.
33. **Huisamen B**, Lochner A. GSK-3 protein and the heart – friend or foe? *SA Heart*. 7(1): 48-57. 2010.
34. Webster I, Friedrich SO, Lochner A, **Huisamen B**. AICAR and ZMP unmask differential effects of AMP Kinase on glut4 translocation and insertion in the membranes of cardiomyocytes. *Cardiovasc J Afr* 21(2):72-78, 2010.
35. Webster I, **Huisamen B**, Du Toit EF, Lochner A. The effect of long term swim training on physiological stress levels in the rat. *Medical Technology SA* 24(2) 2010.
36. **Huisamen B**, Pêrel SJC, Friedrich SO, Salie R, Strijdom H, Lochner A. AngII receptor antagonism improves nitric oxide production, eNOS and PKB expression in hearts from a rat model of insulin resistance. *Mol Cell Biochem* 349:21-31, 2011.
37. **Huisamen B**, Genis A, Lochner A. Pre-treatment with a DPP-4 inhibitor is infarct sparing in hearts from obese, pre-diabetic rats. *Cardiovasc Drugs Ther* 25:13-20. 2011

38. George C, Lochner A, **Huisamen B**. The efficacy of *Prosopis glandulosa* as antidiabetic treatment in rat models of diabetes and insulin resistance. *J Ethnopharmacology*, 137:298-304, 2011.
39. Webster I, **Huisamen B**, Du Toit EF. Creatine and Exercise – Strong evidence for stronger heart muscle? *Journal of Exercise Physiology (online)*, 14(5): 2011. ISSN 1097-9751.
40. **Huisamen B**, D Dietrich, D Blackhurst, Flepisi B, Lochner A. Early cardiovascular changes occurring in diet-induced obese, insulin resistant rats. *Molecular and Cellular Biochemistry: Volume 368 (1):37-45*, 2012.
41. **Huisamen B**. Editorial: Cyclic AMP and PKA: How can a lot of good come from the potentially bad? *Cardiovasc Drugs Ther* 26:435-436, 2012
42. Webster I, Du Toit EF, **Huisamen B**, Lochner A. The effect of creatine supplementation on myocardial function, mitochondrial respiration and susceptibility to ischaemia/reperfusion injury in sedentary and exercised rats. *Acta Physiol (Oxf)*. 2012; 206(1):6-19. doi: 10.1111/j.1748-1716.2012.02463.x. 2012.
43. Lochner A, **Huisamen B**, Nduhirabandi F. Cardioprotective effect of melatonin against ischaemia/reperfusion damage. *Frontiers in Bioscience, Elite*, 5, 305-315, January 1, 2013
44. **Huisamen B**, George C, Dietrich D, Genade S, Lochner A. Cardioprotective and anti-hypertensive effects of *Prosopis glandulosa* in rat models of pre-diabetes. *Cardiovasc J of Africa* 24(2):10-16, 2013
45. Flepisi BT, **Huisamen B**. The consequences of long-term glycogen synthase kinase-3 inhibition on normal and insulin resistant rat hearts. *Cardiovasc Drugs Ther* 27:381–392, 2013.
46. Webster I, Smith A, Lochner A, **Huisamen B**. Sanguinarine Non- Versus Re-Circulation During Isolated Heart Perfusion - A Jekyll and Hyde Effect? *Cardiovasc Drugs Ther*. 2014 Jul 16. [Epub ahead of print]
47. Salie R, **Huisamen B**, Lochner A. High carbohydrate and high fat diets protect the heart against ischaemia/reperfusion injury. *Cardiovascular Diabetology*.13:109, 2014. (DOI: 10.1186/s12933-014-0109-8)
48. Nduhirabandi F, **Huisamen B**, Strijdom H, Blackhurst D, Lochner A. Short-term melatonin consumption protects the heart of obese rats independent of body weight change and visceral adiposity. *J Pineal Res*. 57:317-332, 2014 (doi: 10.1111/jpi.12171)
49. George C, Smith C, Isaacs AW, **Huisamen B**. Chronic *Prosopis glandulosa* treatment blunts neutrophil infiltration and enhances muscle repair after contusion injury. *Nutrients* 7:815-830, 2015
50. George C, Dietrich D, **Huisamen B**. The effect of chronic *Prosopis glandulosa* treatment on muscle force development and fatigue tolerance in slow-twitch muscle. *British J Appl Sci & Tech* 10:1-10, 2015.
51. Espach Y, Lochner A, Strijdom H, **Huisamen B**. ATM protein kinase signalling, type 2 diabetes and cardiovascular disease. *Cardiovasc Drugs Ther* 29:51-58, 2015
52. **Huisamen B**, Lubelwana-Hafver T, Lumkwana D, Lochner A. The impact of chronic Glycogen synthase kinase-3 inhibition on remodelling of normal and pre-diabetic rat hearts. *Cardiovasc Drugs Ther* 2016 Jun;30(3):237-46. doi: 10.1007/s10557-016-6665-2.
53. Dlodla PV, Muller CJ, Joubert E, Louw J, Gabuza KB, **Huisamen B**, Essop MF, Johnson R. Phenylpyruvic Acid-2-O-β-D-Glucoside Attenuates High Glucose-Induced Apoptosis in H9c2 Cardiomyocytes. *Planta Med*. 2016 Jul 12. [Epub ahead of print]
54. B Jack, C Malherbe, **B Huisamen**, K Gabuza, S Mazibuko-Mbeje, A Schulze, E Joubert, CJF Muller, J Louw, C Pheiffer. Characterization of anti-obesity compounds in honeybush tea (*Cyclopia* spp.) using liquid-liquid fractionation. *South African Journal of Botany*. Published ahead of print, September 2016, <http://dx.doi.org/10.1016/j.sajb.2016.08.007>

55. C George, **B Huisamen**, D Dietrich. Cardioprotective and anti-hypertensive effects of *Prosopis glandulosa* in rat models of pre-diabetes. *South African Journal of Diabetes and Vascular Disease* 2016, 13:61-67.
56. PV. Dlodla, CJF Muller, E Joubert, J Louw, MF Essop, KB Gabuza, S Ghoor, **B Huisamen** and R Johnson. Aspalathin Protects the Heart against Hyperglycemia-Induced Oxidative Damage by Up-Regulating Nrf2 Expression.. *Molecules* 2017, 22, 129; doi:10.3390/molecules22010129.
57. R Johnson, PV Dlodla, CJ F Muller, **B Huisamen**, M F Essop and J Louw. The Transcription Profile Unveils the Cardioprotective Effect of Aspalathin against Lipid Toxicity, in an In Vitro H9c2 Model.: *Molecules* 2017, 22, 219; doi: 10.3390/molecules22020219
58. I Webster, E Marais, G Maarman, **B Huisamen**, A Lochner Myocardial susceptibility to ischaemia/reperfusion in obesity: a re-evaluation of the effects of age. *BMC Physiology* 17:3, March 2017.
59. C Westcott, A Genis, M Mthethwa, D Van Vuuren, **B Huisamen**, H Strijdom Fenofibrate protects endothelial cells via a nitric oxide synthase-independent mechanism. *SA Heart* 2017, 14(1): 22-34.
60. F Nduhirabandi, **B Huisamen**, H Strijdom, A Lochner. Role of melatonin in glucose uptake by cardiomyocytes from insulin-resistant Wistar rats. *Cardiovasc J Afr.* 2017 May 17;28:1-9. doi: 10.5830/CVJA-2017-018.
61. I Webster, A Smith, A Lochner, **B Huisamen**. The Role of MKP-1 in Insulin-Induced Cardioprotection. *Cardiovasc Drugs Ther* DOI 10.1007/s10557-017-6731-4, 2017.
62. SE Smit, R Johnson, MA Van Vuuren, **B Huisamen**. Myocardial Glucose Clearance by Aspalathin Treatment in Young, Mature and Obese, Insulin-Resistant Rats. *Planta Medica* 2018; 84:75-82 DOI <https://doi.org/10.1055/s-0043-117415>
63. BU. Jack, CJ Malherbe, EL Willenburg, D de Beer, **B Huisamen**, E. Joubert, CJF Muller, J Louw, C Pheiffer. A polyphenol-enriched fraction of *Cyclopia intermedia* selectively affect lipogenesis in 3T3-L1 adipocytes. *Planta Medica* 2018, 84:100-110.
64. M Thomas, T Davis, B Loos, B Sishi, **B Huisamen**, H Strijdom, A-M Engelbrecht. Autophagy is essential for the maintenance of amino acids and ATP levels during acute amino acid starvation in MDAMB231 cells. *Cell Biochemistry & Function* 2018, 1-15. DOI: 10.1002/cbf.3318.
65. A Lochner, E Marais, **B Huisamen**. Melatonin and cardioprotection against ischaemia/reperfusion injury: What's new? A review. *J Pineal Res* 2018; 65:e12490. DOI: 10.1111/jpi.12390.
66. M Blignaut, Y Espach, M Van Vuuren, K Dhanabalan, **B Huisamen**. Revisiting the Cardiotoxic Effect of Chloroquine. *Cardiovasc Drugs Ther* 2019, 33:1-11. Doi: 10.1007/s10557-018-06847-9.
67. M Blignaut, B Loos, SW Botchway, AW Parker, **B Huisamen**. Ataxia-telangiectasia Mutated is located in cardiac mitochondria and impacts oxidative phosphorylation. *Nature Sci Rep* 2019, 9:4782. Doi:10.1038/s41598-019-41108-1.
68. JI Layman, DL Pereira, N Chellan, **B Huisamen**, SH Kotzé. A Histomorphometric study on the hepatoprotective effects of a green rooibos extract in a diet-induced obese rat model. *Acta Histochemica* 2019, 121:646-656.
69. K. Dube, K. Dhanabalan, R. Salie, M. Blignaut, **B. Huisamen**, A. Lochner. Melatonin has profound effects on mitochondrial dynamics in myocardial ischaemia/reperfusion. *Heliyon* 5 (2019) e02659.
70. K Dhanabalan, **B Huisamen**, A Lochner. Mitochondrial oxidative phosphorylation and mitophagy in myocardial ischaemia/reperfusion: effects of chloroquine. *Cardiovasc J Afr.* 2019,30:1-11. doi: 10.5830/CVJA-2019-067. [Epub ahead of print].
71. Dlodla PV, CJF Muller, J Louw, SE Mazubuko-Mbeje, L Tiano, S Silverstri, P Orlando, F Marcheggiani, I Cirilli, N Chellan, S Ghoor, BB Nkambule, M F Essop, **B Huisamen**, R Johnson. The Combination Effect of Aspalathin and Phenylpyruvic Acid-2-O-β-d-glucoside from Rooibos against Hyperglycemia-Induced Cardiac Damage: An In Vitro Study. *Nutrients.* 2020 Apr; 12(4): 1151. Published online 2020 Apr 20. doi: 10.3390/nu1204115.

72. Sangweni NF, M Moremane, S Riedel, D van Vuuren, **B Huisamen**, L Mabasa, R Barry R Johnson. The Prophylactic Effect of Pinocembrin Against Doxorubicin-Induced Cardiotoxicity in an In Vitro H9c2 Cell Model. *Front Pharmacol.* 2020; 11: 1172. Published online 2020 Aug 5. doi: 10.3389/fphar.2020.01172.
73. Smit SE, Manirafasha C, Marais E, Johnson R, **B Huisamen**. Cardioprotective function of green rooibos (*Aspalathus Linearis*) extract supplementation in *ex vivo* ischemic, pre-diabetic rat hearts. *Planta Medica* 2021. Doi: 10.1055/a-1239-9236.